CytomX Therapeutics

KEYTRUDA And CX-2051 Trials Will Expand Immuno-Oncology Reach Despite Risks

AnalystHighTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

17 Aug 25

Updated

17 Aug 25

AnalystHighTarget's Fair Value

US$8.00

75.0% undervalued

17 Aug

US$2.00

61.3%

7.5%

Author's Valuation

US$8.0

75.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$8.0

75.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-15.33%

Biotech revenue growth rate

12.78%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$29.66m

Earnings '28

118.96x

PE Ratio '28

US$3.53b

Market Cap '28

US$3.53b

Market Cap '28

362.31m

No. shares '28

US$9.74

Share Price '28

US$9.74 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$8.00

Fair Value '25